In:
Tumori Journal, SAGE Publications, Vol. 101, No. 4 ( 2015-07), p. 398-403
Abstract:
The aim of this retrospective multicenter study was to evaluate the impact of progesterone receptor (PgR) loss on locoregional recurrence in patients with estrogen receptor (ER)-positive primary breast cancer and ER-positive locoregional recurrence. Patients and Methods Eight Italian oncology centers collected data from consecutive patients with ER-positive breast cancer and a subsequent ER-positive locoregional recurrence. Results Data were available for 265 patients diagnosed with breast cancer between 1990 and 2009. Median metastasis-free survival was 111 months in patients with PgR-positive primary tumors and locoregional recurrence (PgR pos ), 38 months in patients with PgR-negative primary tumors and locoregional recurrence (PgR neg ), and 63 months in patients with PgR-positive primary tumors and PgR-negative locoregional recurrence (PgR loss ). In multivariate analysis, PgR status was independently associated with metastasis-free survival, with a hazard ratio of 2.84 (95% CI 1.34-6.00) for PgR neg compared with PgR pos , and 2.93 (95% CI: 1.51-5.70) for PgR loss compared with PgR pos . Conclusions PgR absence was found to be a negative prognostic factor in breast cancer patients with ER-positive locoregional recurrence. Thus, PgR status could be a biological marker in ER-positive recurrent breast cancer.
Type of Medium:
Online Resource
ISSN:
0300-8916
,
2038-2529
Language:
English
Publisher:
SAGE Publications
Publication Date:
2015
detail.hit.zdb_id:
280962-X
detail.hit.zdb_id:
2267832-3